Membrane-anchored, CSV-targeted IL-12 localizes cytokine signaling at CSV+ tumor cells, boosting Th1 responses and enhancing CD8+ T-cell and NK-cell cytotoxicity (perforin/granzyme, Fas/FasL, IFN-γ), leading to immune-mediated killing; CSV binding itself does not directly lyse cells.